Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2016

View Archived Issues

ProMetic Life Sciences begins rolling submission of BLA for plasminogen

Phase I and phase II extension study results for fitusiran

Sage Therapeutics begins phase II program for SAGE-217 in mood disorders

Phase III study of closed triple combination therapy for asthma begins

Spring Bank and Arbutus to collaborate on preclinical studies of combination for HBV

FDA grants breakthrough therapy designation for TNX-102 SL

Circuit Therapeutics and Lundbeck enter research collaboration

Highly selective spleen tyrosine kinase inhibitor shows potential for autoimmune diseases

Topline results from an intranasal human abuse potential study of Egalet-002

FDA grants priority review to Tesaro's NDA for niraparib

Phase Ia/b data for chimeric fibril-reactive mAb 11-1F4 in patients with AL amyloidosis

Novel CD33-specific CAR T cells show promise in in vitro and in vivo models of AML

Novel forward-oriented therapeutic vector for hemoglobin disorders

JCAR-017 obtains FDA breakthrough therapy designation and EMA PRIME access

FDA grants fast track designation to ASP-0892

MediciNova's MN-166 granted orphan drug status in E.U. for ALS

GlaxoSmithKline patents KMO inhibitors

FDA accepts for review NDA for CCP-08

Sunshine Lake Pharma discloses 5-HT reuptake inhibitors and/or 5-HT1A receptor agonists

Rugen Holdings describes NR2B receptor antagonists

Teijin Pharma develops CDK4/cyclin D3 and CDK6/cyclin D3 inhibitors

Jiangsu Tasly Diyi Pharmaceutical presents antiviral agents

FDA extends PDUFA date for Genentech's ocrelizumab

Janssen applies for approval of daratumumab in Japan

Diurnal submits European pediatric use marketing authorization application for Infacort

Apellis Pharmaceuticals' APL-2 earns fast track designation from FDA

Akebia and Otsuka Pharmaceutical collaborate to develop and commercialize vadadustat in the U.S.

Allergan to acquire LifeCell

FDA gives fast track designation to KemPharm's KP201/IR

Circadian Therapeutics formed as a new Oxford spinout to study sleep and circadian rhythms

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...